CorMedix Inc. (CRMD) Stock Price & Analysis
CorMedix Inc. (CRMD) closed at USD 7.46 on Thursday, October 15, 2026, up 0.95% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 7.39; the Oct 15, 2026 session ranged USD 7.44–7.7 on volume of 1,466,202 shares. Market capitalization is $581.46M, with a 52-week range of USD 6.13–13.02 (NGM). Source: Nexqual, retrieved October 16, 2026 at 05:22 UTC.
Also available as compact Markdown for AI agents: nexqual.com/CRMD.md
Key facts (CRMD)
- Last four reported quarters (through Jun 30, 2026): revenue $462M, net income $187M (40.5% margin), free cash flow $250M (SEC filings).
- Valuation: P/E 3.1x (avg 0.0x at the last 1 fiscal year-ends).
- Analysts: Buy (mean 1.50 on a 1–5 scale) (6 analysts), mean target USD 15.33 (range 13–19).
- Total return with dividends: 1Y -26.0% vs S&P 500 +18.1%; 5Y +50.7% vs S&P 500 +85.1%.
- Next earnings: 2026-11-16, EPS estimate USD -0.11, revenue estimate $53.2M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (CRMD)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $191K | $65K | — | $43.5M | $312M | $462M |
| Gross profit | $42K | $62K | — | $40.3M | $276M | — |
| Operating income | -$29.4M | -$30.6M | -$49.0M | -$22.4M | $150M | $217M |
| Net income | -$28.2M | -$29.7M | -$46.3M | -$17.9M | $163M | $187M |
| EPS (diluted) | -$0.75 | -$0.74 | -$0.91 | -$0.30 | $2.04 | — |
| Free cash flow | -$22.6M | -$24.6M | -$38.7M | -$50.7M | $173M | $250M |
| Gross margin | 22.0% | 94.3% | — | 92.7% | 88.5% | — |
| Operating margin | -15417.5% | -46819.9% | — | -51.4% | 48.2% | 47.0% |
| Net margin | -14774.7% | -45409.9% | — | -41.2% | 52.3% | 40.5% |
| Revenue growth | -20.2% | -65.7% | — | — | +617.0% | — |
| Cash + short-term investments | $65.5M | $58.8M | $76.0M | $51.7M | $149M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (CRMD)
P/E 3.1x · P/S 1.3x · P/FCF 2.3x · P/B 1.3x · FCF yield 43.07% · Earnings yield 32.19%
P/E at fiscal year-ends: Dec 2025 0.0x.
Analysts (CRMD)
Consensus Buy (mean 1.50 on a 1–5 scale), 6 analysts; mean target USD 15.33 (low 13, high 19).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-23 | Oppenheimer | Initiated | Outperform | $15 |
| 2026-08-14 | RBC Capital | Target raised | Outperform | $13 → $14 |
| 2026-07-07 | RBC Capital | Target lowered | Outperform | $14 → $13 |
Total return (dividends reinvested) (CRMD)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | -26.0% | +50.7% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -26.1% | +8.5% |
| Volatility (annualized) | 64.7% | 75.7% |
| Max drawdown | -50.9% (Dec 2025→Mar 2026) | -60.3% (Aug 2022→Sep 2022) |
Key Statistics (as of October 16, 2026 at 05:22 UTC)
| Price | USD 7.46 |
|---|---|
| Change | ▲ 0.95% (up) |
| Previous Close | USD 7.39 |
| Open | USD 7.5 |
| Day Range | USD 7.44 – 7.7 |
| 52-Week Range | USD 6.13 – 13.02 |
| Volume | 1,466,202 shares |
| Market Cap | $581.46M |
| Exchange | NGM |
Technical Analysis (CRMD)
Nexqual's technical model rates CRMD "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:22 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 40.46 (neutral) |
| vs SMA50 | Below (USD 7.83) |
| MACD | -0.15 (negative) |
Analyst Ratings (CRMD)
Wall Street analysts rate CRMD "Buy" based on 6 analysts, with a mean price target of USD 15.33 (range USD 13–19), per Nexqual as of October 16, 2026 at 05:22 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 15.33 |
| High Target | USD 19 |
| Low Target | USD 13 |
| Buy / Hold / Sell | 6 / 0 / 0 |
Earnings (CRMD)
| Next Earnings Date | 2026-11-16 |
|---|---|
| Revenue Estimate | $53.23M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.29 vs est 0.24 ▲ beat |
| 2026-03-31 | USD 0.35 vs est 0.33 ▲ beat |
| 2025-12-31 | USD 0.16 vs est 0.81 ▼ miss |
| 2025-09-30 | USD 1.41 vs est 0.63 ▲ beat |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financials & Fundamentals (CRMD)
| Total Revenue | $462.25M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +156.50% |
| Gross Margin | +90.21% |
| Operating Margin | +42.10% |
| Profit Margin | +40.49% |
| ROE | +54.93% |
| Debt / Equity | 0.32 |
| Current Ratio | 2.56 |
| Total Cash | $256.69M |
| Total Debt | $147.46M |
| Free Cash Flow (fiscal year ended Dec 2025, SEC 10-K) | $172.79M (55.4% of revenue) |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financial Health Score (CRMD)
Nexqual rates CorMedix Inc.'s overall financial health "Strong" across five dimensions, as of October 16, 2026 at 05:22 UTC.
| Growth | Strong — Revenue +617% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 90%, operating 42% |
| Balance Sheet | Strong — $257M cash vs $147M debt, net cash position |
| Cash Flow | Strong — FCF $173M (FY ended Dec 2025, 10-K), 55% margin |
| Efficiency | Strong — ROE 55%, ROA 24.6% |
Ownership (CRMD)
| Insider Ownership | +7.61% |
|---|---|
| Institutional Ownership | +57.94% |
| Shares Outstanding | 77.94M |
| Float | 65.89M |
| Short % of Float | +20.05% |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Leadership (CRMD)
CorMedix Inc. is led by Joseph Todisco (age 49), CEO & Chairman of the Board of Directors, per Nexqual as of October 16, 2026 at 05:22 UTC.
| CEO & Chairman of the Board of Directors | Joseph Todisco (age 49) |
|---|---|
| Executive VP and Chief Operating & Commercial Officer | Elizabeth Masson-Hurlburt B.A. (age 46) |
| EVP & Chief Financial Officer | Susan Blum (age 52) |
| Senior Vice President of Market Access | Peter Sullivan BCOP, Pharm.D. |
| Executive Director of Clinical Portfolio Management | Jared L. Crandon Pharm.D. |
Major Backers & Investors (CRMD)
Notable institutional backers of CorMedix Inc. include Deep Track Capital, Lp, Royce & Associates LP, American Century ETF Trust-Avantis U.S. Small Cap Value ETF, according to Nexqual as of October 16, 2026 at 05:22 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Deep Track Capital, Lp | 8.05% |
| Royce & Associates LP | 2.79% |
| American Century ETF Trust-Avantis U.S. Small Cap Value ETF | 2.76% |
| UBS Group AG | 2.41% |
| Oberweis Asset Management Inc. | 1.7% |
| OBERWEIS FUNDS-Oberweis Micro-Cap Fund | 1.64% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 11.45% |
| Vanguard Group | 7.94% |
| State Street | 4.06% |
| Geode Capital | 2.5% |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:22 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt